Sagimet Biosciences Inc.
NGM: SGMTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Sagimet Biosciences Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SGMT Z-Score →About Sagimet Biosciences Inc.
Healthcare
Biotechnology
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
📊 Fundamental Analysis
Sagimet Biosciences Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -38.2%, which indicates that capital utilization is currently under pressure.
At a current price of $5.30, SGMT currently sits at the 35th percentile of its 52-week range (Range: $2.02 - $11.41).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$172.70M
Trailing P/E
--
Forward P/E
-2.78
Beta (5Y)
3.21
52W High
$11.41
52W Low
$2.02
Avg Volume
528K
Day High
Day Low